3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Classical hematology
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
2046
Triple Negative Breast Neoplasms
208
Neoplasm Metastasis
133
Neoplasms
119
Carcinoma, Non-Small-Cell Lung
96
Breast Neoplasms, Male
95
Ovarian Neoplasms
89
Colorectal Neoplasms
70
Lung Neoplasms
67
Carcinoma, Intraductal, Noninfiltrating
63
Melanoma
57
Prostatic Neoplasms
55
Pancreatic Neoplasms
47
Breast Carcinoma In Situ
42
Stomach Neoplasms
38
Colonic Neoplasms
37
Brain Neoplasms
36
Carcinoma, Renal Cell
35
Inflammatory Breast Neoplasms
33
Head and Neck Neoplasms
32
Urinary Bladder Neoplasms
29
Pain
29
Small Cell Lung Carcinoma
27
Squamous Cell Carcinoma of Head and Neck
26
Endometrial Neoplasms
25
Sarcoma
23
Fatigue
23
Uterine Cervical Neoplasms
21
Esophageal Neoplasms
21
Multiple Myeloma
18
Interventions
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms, Second Primary
×
Breast
×
Clear all
NCT00638963
2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2
Terminated
6 enrolled
9 charts